Business Description
Ligand Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US53220K5048
Share Class Description:
STU:LGDN: Ordinary Shares - Class BTotal Employee Number:
47Description
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.75 | |||||
Equity-to-Asset | 0.65 | |||||
Debt-to-Equity | 0.45 | |||||
Debt-to-EBITDA | 2.02 | |||||
Interest Coverage | 18.09 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 8.58 | |||||
Beneish M-Score | -3.59 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 4.3 | |||||
3-Year EBITDA Growth Rate | 22.5 | |||||
3-Year EPS without NRI Growth Rate | 19.3 | |||||
3-Year FCF Growth Rate | -35.9 | |||||
3-Year Book Growth Rate | 13.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 21.63 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 18.89 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 58.65 | |||||
9-Day RSI | 52.24 | |||||
14-Day RSI | 53.32 | |||||
3-1 Month Momentum % | 42.13 | |||||
6-1 Month Momentum % | 75 | |||||
12-1 Month Momentum % | 141.38 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 21.28 | |||||
Quick Ratio | 21 | |||||
Cash Ratio | 19.46 | |||||
Days Inventory | 308.9 | |||||
Days Sales Outstanding | 66.58 | |||||
Days Payable | 147.04 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -5.3 | |||||
Shareholder Yield % | -5.5 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 95.27 | |||||
Operating Margin % | 36.88 | |||||
Net Margin % | 55.95 | |||||
EBITDA Margin % | 81.5 | |||||
FCF Margin % | 39.33 | |||||
OCF Margin % | 45.11 | |||||
ROE % | 16.73 | |||||
ROA % | 11.95 | |||||
ROIC % | 11.69 | |||||
ROC (Joel Greenblatt) % | 390.71 | |||||
ROCE % | 15.38 | |||||
Years of Profitability over Past 10-Year | 6 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 41.05 | |||||
Forward PE Ratio | 32.7 | |||||
PE Ratio without NRI | 36.28 | |||||
Shiller PE Ratio | 54.54 | |||||
Price-to-Owner-Earnings | 32.55 | |||||
PEG Ratio | 8.64 | |||||
PS Ratio | 22.45 | |||||
PB Ratio | 6.08 | |||||
Price-to-Tangible-Book | 8.93 | |||||
Price-to-Free-Cash-Flow | 53.69 | |||||
Price-to-Operating-Cash-Flow | 49.61 | |||||
EV-to-EBIT | 30.05 | |||||
EV-to-Forward-EBIT | 34.42 | |||||
EV-to-EBITDA | 25.59 | |||||
EV-to-Forward-EBITDA | 34.42 | |||||
EV-to-Revenue | 20.86 | |||||
EV-to-Forward-Revenue | 20.12 | |||||
EV-to-FCF | 50.22 | |||||
Price-to-GF-Value | 1.69 | |||||
Price-to-Projected-FCF | 4.26 | |||||
Price-to-Median-PS-Value | 2.21 | |||||
Price-to-Graham-Number | 3.8 | |||||
| Price-to-Net-Current-Asset-Value | 18.32 | |||||
| Price-to-Net-Cash | 23.59 | |||||
Earnings Yield (Greenblatt) % | 3.33 | |||||
FCF Yield % | 1.88 | |||||
Forward Rate of Return (Yacktman) % | 15.5 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Ligand Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 249.354 | ||
| EPS (TTM) (€) | 6.069 | ||
| Beta | 1.1723 | ||
| 3-Year Sharpe Ratio | 1.19 | ||
| 3-Year Sortino Ratio | 2.72 | ||
| Volatility % | 42.81 | ||
| 14-Day RSI | 53.32 | ||
| 14-Day ATR (€) | 8.426745 | ||
| 20-Day SMA (€) | 261.4 | ||
| 12-1 Month Momentum % | 141.38 | ||
| 52-Week Range (€) | 116 - 286 | ||
| Shares Outstanding (Mil) | 20.04 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ligand Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ligand Pharmaceuticals Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Ligand Pharmaceuticals Investor Day | 2026-12-08 10:30 | In 125 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-06 08:30 | In 93 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 92 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-06 08:30 | In 1 day | ||
| Second quarter earnings results for 2026 | 2026-08-06 | 260.00 (+3.17%) | ||
| General meeting for 2026 | 2026-06-05 11:30 | 202.00 (+1.00%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 08:30 | 196.00 (-1.51%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 196.00 (-1.51%) | ||
| Guidance call for 2026 | 2026-03-25 15:45 | 172.00 (+1.78%) | ||
| 38th Annual ROTH Conference | 2026-03-23 13:00 | 176.00 (-1.68%) |
Show
Entries
Ligand Pharmaceuticals Inc Frequently Asked Questions
What is Ligand Pharmaceuticals Inc(STU:LGDN)'s stock price today?
The current price of STU:LGDN is €260.00. The 52 week high of STU:LGDN is €286.00 and 52 week low is €116.00.
When is next earnings date of Ligand Pharmaceuticals Inc(STU:LGDN)?
The next earnings date of Ligand Pharmaceuticals Inc(STU:LGDN) is 2026-08-06.
Does Ligand Pharmaceuticals Inc(STU:LGDN) pay dividends? If so, how much?
Ligand Pharmaceuticals Inc(STU:LGDN) does not pay dividend.
Press Release
Articles on Ligand Pharmaceuticals Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers